Bio Pharma Dive
OCTOBER 23, 2023
Three essential components to create impactful real-world evidence with a 360-degree patient journey.
Pharmaceutical Technology
OCTOBER 24, 2023
The FDA released a draft guidance giving firms recommendations on provider-directed communication for off-label drug use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 24, 2023
Pharma dips toe into tech adoption, but is it deep enough? Mike.
Bio Pharma Dive
OCTOBER 26, 2023
Company shares fell Thursday as the company adjusted its medium-term guidance for sales of new products like Reblozyl, Camzyos and Abecma.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Pharmaceutical Technology
OCTOBER 24, 2023
Pear Therapeutics was a pioneer in developing DTx for neurological conditions traditionally treated by evidence-based behavioural or psychological management strategies.
pharmaphorum
OCTOBER 26, 2023
The longitudinal history of medicines innovation: Part One Mike.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
OCTOBER 23, 2023
The trial, which is ongoing in the U.K. and New Zealand, has been on hold in the U.S. since late last year as the FDA sought more details on Verve’s in vivo treatment for heart disease.
XTalks
OCTOBER 26, 2023
Fall marks the beginning of the “flu season,” the period during the year when influenza (flu) viruses are in increased circulation and cause illness at higher rates than usual. The season also marks the increased circulation of other respiratory viruses, including SARS-CoV-2, which causes COVID-19, and respiratory syncytial virus (RSV). In the US, the flu or respiratory virus season typically begins in the fall and peaks in the winter, usually between December and February, but it can last as la
Bio Pharma Dive
OCTOBER 23, 2023
Effective marketing measurement requires objectivity, connected data, transparency, a track record of innovation and a proven ability to execute.
Pharmaceutical Technology
OCTOBER 24, 2023
SpeechDx will contain recorded voice samples and other data, which will be used to develop algorithms for creating new speech biomarkers.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 26, 2023
Many tiny organisms including bacteria, fungi and viruses normally live on our bodies, and even inside us. These are called the microbiome. The large number of these organisms living in the gastrointestinal tract are collectively known as the gut microbiome.
Pharma Times
OCTOBER 23, 2023
STARMAP will accelerate the selection of AZ’s best molecule candidates - News - PharmaTimes
Bio Pharma Dive
OCTOBER 24, 2023
The money will be spread across three investment funds and comes at a time when investment into biotech remains shakier than in years past.
Pharmaceutical Technology
OCTOBER 27, 2023
The UK NICE has recommended the use of AbbVie’s foslevodopa–foscarbidopa (Produodopa) for the treatment of advanced Parkinson’s disease.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 25, 2023
Adults diagnosed with attention-deficit/hyperactivity disorder ( ADHD) are almost three times more likely to go on to develop dementia, according to a new study that looked at 109,218 adults with and without the condition over a period of 17 years. The researchers, from institutions in Israel and the US, found that 13.
Pharma Times
OCTOBER 23, 2023
STARMAP will accelerate the selection of AZ’s best molecule candidates - News - PharmaTimes
Bio Pharma Dive
OCTOBER 27, 2023
In a wide-ranging interview, Bristol Myers’ Ken Rhodes talked biomarkers, diseases of interest and why the company is far from done with neuroscience-focused deals.
Pharmaceutical Technology
OCTOBER 27, 2023
(CST-2032 + nadolol) is under clinical development by CuraSen Therapeutics and currently in Phase II for Dementia.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 24, 2023
If the idea of driving down a winding road makes you feel queasy, spare a thought for the mice employed in a new study, which sought to pinpoint the brain cells responsible for motion sickness.
Pharma Times
OCTOBER 26, 2023
Thousands of patients with heart failure are set to benefit from the expansion - News - PharmaTimes
Bio Pharma Dive
OCTOBER 23, 2023
The clearance of the pentavalent shot Penbraya adds to Pfizer’s infectious disease portfolio as it adjusts to slumping COVID-19 vaccine sales.
Pharmaceutical Technology
OCTOBER 26, 2023
The potential for using gene therapies to treat sickle cell disease is high, but their durability and high price point invite scrutiny.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 26, 2023
The Indian Council of Medical Research (ICMR) has invited proposals to establish Ayush-ICMR Advanced Centre for Integrative Health Research (AI-ACIHR) at the All India Institute of Medical Sciences (AIIMS) under Extramural Programme. This is following a Memorandum of Agreement (MoA) signed between the Union Ministry of Ayush and the ICMR at an inter-ministerial level.
Pharma Times
OCTOBER 25, 2023
The APPG has called for urgent improvements in rural and ethnically diverse-areas - News - PharmaTimes
Bio Pharma Dive
OCTOBER 24, 2023
The startup is taking aim at an inflammation-linked protein known as TSLP, which is the target of an approved asthma medicine.
Pharmaceutical Technology
OCTOBER 25, 2023
The AD and PD drug aims to reduce the level of neurotoxic proteins, thereby improving information flow across the axonal transport
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 24, 2023
The National Accreditation Board for Hospitals and Healthcare Providers (NABH) has released the first edition of NABH Certification standards for stroke care centres. It has urged all the centres across the country to apply for accreditation depending on the self-assessment of the standards.
Pharma Times
OCTOBER 25, 2023
The company will launch a clinical investigation of EA-2351 for geographic atrophy - News - PharmaTimes
Bio Pharma Dive
OCTOBER 26, 2023
Executives at the biotech say they’re trying to get ahead of the payer and production challenges that will face their gene editing treatment exa-cel, which is now under FDA review.
Pharmaceutical Technology
OCTOBER 27, 2023
(CST-2032 + nadolol) is under clinical development by CuraSen Therapeutics and currently in Phase II for Dementia.
Expert insights. Personalized for you.
284 
Let's personalize your content